BCYC
Price
$8.56
Change
+$0.52 (+6.47%)
Updated
Jul 18 closing price
Capitalization
592.81M
10 days until earnings call
RCUS
Price
$9.38
Change
+$0.23 (+2.51%)
Updated
Jul 21, 10:43 AM (EDT)
Capitalization
968.85M
10 days until earnings call
Interact to see
Advertisement

BCYC vs RCUS

Header iconBCYC vs RCUS Comparison
Open Charts BCYC vs RCUSBanner chart's image
Bicycle Therapeutics
Price$8.56
Change+$0.52 (+6.47%)
Volume$501.92K
Capitalization592.81M
Arcus Biosciences
Price$9.38
Change+$0.23 (+2.51%)
Volume$201
Capitalization968.85M
BCYC vs RCUS Comparison Chart in %
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. RCUS commentary
Jul 21, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Hold and RCUS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 21, 2025
Stock price -- (BCYC: $8.56 vs. RCUS: $9.15)
Brand notoriety: BCYC and RCUS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 183% vs. RCUS: 43%
Market capitalization -- BCYC: $592.81M vs. RCUS: $968.85M
BCYC [@Biotechnology] is valued at $592.81M. RCUS’s [@Biotechnology] market capitalization is $968.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $286.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileRCUS’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • RCUS’s FA Score: 0 green, 5 red.
According to our system of comparison, BCYC is a better buy in the long-term than RCUS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 5 TA indicator(s) are bullish while RCUS’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 5 bullish, 5 bearish.
  • RCUS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RCUS is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а +7.00% price change this week, while RCUS (@Biotechnology) price change was -1.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.68%. For the same industry, the average monthly price growth was +13.07%, and the average quarterly price growth was +34.43%.

Reported Earning Dates

BCYC is expected to report earnings on Jul 31, 2025.

RCUS is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+2.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RCUS($969M) has a higher market cap than BCYC($593M). RCUS (-38.549) and BCYC (-38.857) have similar YTD gains . BCYC has higher annual earnings (EBITDA): -200.61M vs. RCUS (-377M). RCUS has more cash in the bank: 997M vs. BCYC (793M). BCYC has less debt than RCUS: BCYC (8.33M) vs RCUS (60M). RCUS has higher revenues than BCYC: RCUS (141M) vs BCYC (25.7M).
BCYCRCUSBCYC / RCUS
Capitalization593M969M61%
EBITDA-200.61M-377M53%
Gain YTD-38.857-38.549101%
P/E RatioN/AN/A-
Revenue25.7M141M18%
Total Cash793M997M80%
Total Debt8.33M60M14%
FUNDAMENTALS RATINGS
BCYC vs RCUS: Fundamental Ratings
BCYC
RCUS
OUTLOOK RATING
1..100
3250
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
53
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9697
PRICE GROWTH RATING
1..100
6161
P/E GROWTH RATING
1..100
10099
SEASONALITY SCORE
1..100
19n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (21) in the null industry is in the same range as RCUS (53) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to RCUS’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as RCUS (100) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to RCUS’s over the last 12 months.

BCYC's SMR Rating (96) in the null industry is in the same range as RCUS (97) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to RCUS’s over the last 12 months.

BCYC's Price Growth Rating (61) in the null industry is in the same range as RCUS (61) in the Pharmaceuticals Major industry. This means that BCYC’s stock grew similarly to RCUS’s over the last 12 months.

RCUS's P/E Growth Rating (99) in the Pharmaceuticals Major industry is in the same range as BCYC (100) in the null industry. This means that RCUS’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCRCUS
RSI
ODDS (%)
Bullish Trend 4 days ago
85%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
87%
Bearish Trend 4 days ago
87%
Momentum
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
78%
MACD
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
81%
Bearish Trend 4 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 4 days ago
76%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 5 days ago
80%
Declines
ODDS (%)
Bearish Trend 22 days ago
87%
Bearish Trend 15 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
86%
Bearish Trend 4 days ago
84%
Aroon
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RCUS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYCUX44.580.75
+1.71%
Rydex Utilities C
QRLVX34.110.07
+0.21%
Federated Hermes MDT Large Cap Value R
FOSFX74.41-0.17
-0.23%
Fidelity Overseas
IIVLX20.46-0.07
-0.34%
Transamerica Small/Mid Cap Value C
SCUIX30.04-0.16
-0.53%
Hartford Schroders US Small Cap Opps I

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with XNCR. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+6.47%
XNCR - BCYC
55%
Loosely correlated
-1.10%
RLAY - BCYC
50%
Loosely correlated
-4.11%
RPTX - BCYC
48%
Loosely correlated
N/A
INO - BCYC
47%
Loosely correlated
+1.46%
RCUS - BCYC
44%
Loosely correlated
-2.87%
More

RCUS and

Correlation & Price change

A.I.dvisor indicates that over the last year, RCUS has been loosely correlated with XNCR. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if RCUS jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RCUS
1D Price
Change %
RCUS100%
-2.87%
XNCR - RCUS
51%
Loosely correlated
-1.10%
IDYA - RCUS
48%
Loosely correlated
-2.26%
ACLX - RCUS
48%
Loosely correlated
-4.74%
TRDA - RCUS
48%
Loosely correlated
-1.88%
OCUL - RCUS
47%
Loosely correlated
-0.44%
More